Tema Etfs LLC Invests $2.23 Million in DexCom, Inc. (NASDAQ:DXCM)

Tema Etfs LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 28,643 shares of the medical device company's stock, valued at approximately $2,228,000.

Other large investors also recently modified their holdings of the company. Norges Bank bought a new stake in shares of DexCom during the fourth quarter worth about $385,367,000. Congress Asset Management Co. lifted its position in DexCom by 5,456.9% in the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after acquiring an additional 1,332,522 shares in the last quarter. Fisher Funds Management LTD acquired a new position in DexCom during the 4th quarter valued at about $96,507,000. Northern Trust Corp boosted its stake in DexCom by 22.2% during the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after purchasing an additional 753,857 shares during the last quarter. Finally, Jennison Associates LLC increased its holdings in DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after purchasing an additional 710,858 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 13,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the transaction, the executive vice president now directly owns 105,602 shares of the company's stock, valued at approximately $7,432,268.76. This trade represents a 10.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jereme M. Sylvain sold 7,000 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the sale, the executive vice president now directly owns 135,482 shares in the company, valued at $10,002,636.06. The trade was a 4.91% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 66,926 shares of company stock worth $4,734,384. Company insiders own 0.32% of the company's stock.

DexCom Stock Performance

Shares of DexCom stock traded down $2.45 on Wednesday, reaching $84.89. 2,673,172 shares of the company traded hands, compared to its average volume of 4,362,861. The company has a 50 day moving average of $72.71 and a 200 day moving average of $77.87. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $131.76. The firm has a market capitalization of $33.29 billion, a PE ratio of 59.36, a PEG ratio of 2.30 and a beta of 1.43. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business's quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.32 earnings per share. Equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of recent research reports. Robert W. Baird dropped their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Morgan Stanley increased their price target on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Citigroup lifted their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Cfra Research upgraded shares of DexCom to a "hold" rating in a research note on Friday, March 21st. Finally, Piper Sandler lowered their target price on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $98.11.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.